{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:27:51Z","timestamp":1791091671620,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2527,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1093\/annonc\/mds250","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T05:17:14Z","timestamp":1348982234000},"page":"133-138","source":"Crossref","is-referenced-by-count":52,"title":["Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds250_bb0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds250_bb0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","article-title":"Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study","volume":"26","author":"Petrek","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0020","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1200\/JCO.2004.01.159","article-title":"Web-based survey of fertility issues in young women with breast cancer","volume":"22","author":"Partridge","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1095\/biolreprod52.2.365","article-title":"Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys","volume":"52","author":"Ataya","year":"1995","journal-title":"Biol Reprod"},{"key":"10.1093\/annonc\/mds250_bb0030","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/oxfordjournals.humrep.a019457","article-title":"Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by gonodotrophin-releasing hormone agonist in parallel to chemotherapy","volume":"11","author":"Blumenfeld","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1093\/annonc\/mds250_bb0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120300678828596","article-title":"Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus by chemotherapy","volume":"9","author":"Blumenfeld","year":"2000","journal-title":"Lupus"},{"key":"10.1093\/annonc\/mds250_bb0040","first-page":"25a","article-title":"Preventing chemotherapy-associated amenorrhea (CRA) with leuprolide in young women with early-stage breast cancer","volume":"20","author":"Fox","year":"2001","journal-title":"Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/gyno.2001.6181","article-title":"Use of GnRH analogues for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report","volume":"81","author":"Pereya Pacheco","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mds250_bb0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cncr.21646","article-title":"Gonadotrophin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma","volume":"106","author":"Recchia","year":"2006","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds250_bb0055","first-page":"269","article-title":"Effect of the gonodotrophin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in pre-menopausal women with breast cancer","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds250_bb0060","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":"Effect of luteinizing hormone- releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy. The GBG 37 ZORO study","volume":"29","author":"Gerber","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-007-9745-y","article-title":"Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)","volume":"110","author":"Urruticoechea","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mds250_bb0070","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","article-title":"Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds250_bb0075","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1009616","article-title":"Amenorrhea from breast cancer therapy-not a matter of dose","volume":"363","author":"Swain","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds250_bb0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/humupd\/dmh021","article-title":"Fertility preservation in female patients","volume":"10","author":"Sonmezer","year":"2004","journal-title":"Hum Reprod Update"},{"key":"10.1093\/annonc\/mds250_bb0085","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1634\/theoncologist.12-9-1044","article-title":"How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embryo, oocytes or ovaries","volume":"12","author":"Blumenfeld","year":"2007","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mds250_bb0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(81)92301-1","article-title":"Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone","volume":"1","author":"Glode","year":"1981","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds250_bb0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.fertnstert.2007.12.044","article-title":"Gonodotrophin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study","volume":"91","author":"Badawy","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1093\/annonc\/mds250_bb0100","first-page":"13","article-title":"Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer","volume":"22","author":"Fox","year":"2003","journal-title":"Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00001813-200204000-00011","article-title":"Goserelin as ovarian protection in the adjuvant treatment of pre-menopausal breast cancer: a phase II pilot study","volume":"13","author":"Recchia","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"suppl","key":"10.1093\/annonc\/mds250_bb0110","first-page":"15S","article-title":"The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer","volume":"28","author":"Leonard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mds250_bb0115","first-page":"26","article-title":"Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy","author":"Ismail-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2011.34.6890","article-title":"Randomized trial using gonadotrophin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer","volume":"30","author":"Munster","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0125","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/GRF.0b013e3181f96cb1","article-title":"Use of hormonal protection for chemotherapy-induced gonodatoxicity","volume":"53","author":"Kim","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"10.1093\/annonc\/mds250_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.fertnstert.2005.09.013","article-title":"Successful ongoing pregnancies after vitrification of oocytes","volume":"85","author":"Lucerna","year":"2006","journal-title":"Fert Steril"},{"key":"10.1093\/annonc\/mds250_bb0135","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/humrep\/dep289","article-title":"IVF outcome in patients with orthotopically transplanted ovarian tissue","volume":"24","author":"Dolmans","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1093\/annonc\/mds250_bb0140","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1210\/jcem.87.4.8367","article-title":"Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age","volume":"87","author":"Oktay","year":"2002","journal-title":"J. Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds250_bb0145","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bpobgyn.2011.11.008","article-title":"Chemotherapy and fertility","volume":"26","author":"Blumenfeld","year":"2012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1093\/annonc\/mds250_bb0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oxfordjournals.annonc.a057670","article-title":"Late effects of adjuvant oophorectomy and chemotherapy upon pre-menopausal breast cancer patients","volume":"1","author":"International Breast cancer Study Group","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds250_bb0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1996.14.1.46","article-title":"Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for pre-menopausal, node-positive, and estrogen receptor- positive breast cancer patients: a Southwest Oncology Group study","volume":"14","author":"Rivkin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds250_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/annonc\/mdi085","article-title":"Randomized trial of adjuvant ovarian suppression in 926 pre-menopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"16","author":"Arriagada","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds250_bb0165","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djk109","article-title":"Ovarian ablation or suppression in pre-menopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial","volume":"99","author":"Adjuvant Breast Cancer Trials Collaborative Group","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds250_bb0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1005792830054","article-title":"Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications","volume":"43","author":"Del Mastro","year":"1997","journal-title":"Breast Cancer Res Treat"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/1\/133\/5635787\/mds250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:23:31Z","timestamp":1624505011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419370450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0923753419370450"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds250","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717957867.793462169","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}